Cardioplegic solution
View Patent ↗Use of potassium for the production of a cardioplegic solution for the prevention of stone heart development during acute cardiac ventricular fibrillation in connection with cardiopulmonary resuscitation is described, as well as a cardioplegic solution comprising potassium and a method for the prevention of stone heart developement during acute cardiac ventricular fibrillation in connection with cardiopulmonary resuscitation.
1. A method for the prevention of stone heart development during acute cardiac ventricular fibrillation in connection with cardiopulmonary resuscitation, comprising
administering potassium ions in a cardioplegic solution to a patient during prolonged CPR, in an amount effective to obtain cardioplegia, wherein said cardioplegic solution is providing by dissolving said potassium ions in a pharmaceutically acceptable medium in a concentration of 12-30 mM when the potassium ions are injected as a booster solution directly into the heart, and in a concentration of 12-140 mM when the potassium ions are administered as an infusion solution.
2. Method according to claim 1 , wherein potassium in the form of a salt with one or more anions selected from the group consisting of chloride, acetate, lactate, phosphate, carbonate, and bicarbonate is dissolved in the pharmaceutically acceptable medium, optionally together with a vasodilator.
3. Method according to claim 2 , wherein the potassium ion concentration is 16-22 mM when the cardioplegic solution is injected as a booster solution directly into the heart.
4. Method according to claim 2 , wherein potassium chloride is dissolved.
5. Method according to claim 2 , wherein the vasodilator is present and is selected from the group consisting of papaverin, nifedipin, nitroglycerine, nitroprusside, and magnesium.
6. The method according to claim 2 , wherein the pharmaceutically acceptable medium is water.
7. Method according to claim 1 , wherein the cardioplegic solution is administered as a booster solution via direct injection into the coronary vessels, or into the left ventricle, followed by continuous administration of the cardioplegic solution; or infusion via a central venous catheter into the right atrium, the right ventricle or arteria pulmonaris, wherein the potassium ion concentration is incrementally decreased while maintaining the potassium ion concentration in the patient's aortic blood between 15 and 20 mM.
8. Method according to claim 1 , wherein the potassium ion concentration of the heart is decreased after the end of the administration of the cardioplegic solution by infusion of a solution containing insulin and glucose.
9. Method according to claim 1 , wherein the cardioplegic solution is administered to the patient during effective heart compressions.
10. Method according to claim 1 wherein said potassium ion concentration is 16-22 mM when the cardioplegic solution is injected as a booster solution directly into the heart.
11. The method of claim 5 wherein said vasodilator is 40-120 mg of papaverin.
12. Method according to claim 1 , wherein the cardioplegic solution is administered as a booster solution via direct injection into the coronary vessels, or into the left ventricle, followed by continuous administration of the cardioplegic solution; or infusion via a central venous catheter into the right atrium, the right ventricle or arteria pulmonaris, wherein the potassium ion concentration is incrementally decreased to control the potassium ion concentration when reaching the heart to be 12-30 mM.